Alterola Biotech INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OTC.Pink
Alterola Biotech will restate its Q2 2024 financial statements due to an error in the consolidation of its subsidiaries, though the company believes the impact is not material.
OTC.Pink
Alterola Biotech has entered into a convertible promissory note agreement for $310,000 to bolster its working capital.